BrianIRiniMDFASCO

PubMed

• A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with ad...
  Kathryn E Beckermann, Amita Patnaik, Ira Winer, Winston Tan, Babar Bashir, Christos E Kyriakopoulos, Randy F Sweis, Marc Chamberlain, Brian I Rini> ;Investigational New Drugs. 2024 Apr 1
• Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
  Renée Maria Saliby, Chris Labaki, Tejas R Jammihal, Wanling Xie, Maxine Sun, Valisha Shah, Eddy Saad, M Harry Kane, Soki Kashima, Katherine Sadak, Talal El Zarif, Deep...> ;Cancer Cell. 2024 Mar 22
• Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
  Donahue, A., Powles, T., Haanen, J., Larkin, J., Mu, X., Pu, J., Teresi, R., di Pietro, A., Robbins, P., Choueiri, T., Braun, D., Rini, B., Motzer, R.> ;Cancer Discovery. 2024 Mar 1
• Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
  Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson, Vijay Kasturi, David F McDermott, Sumanta K Pal, Camillo Porta, Bria...> ;The Oncologist. 2024 Mar 4
• Microbiome subsets determine tumor prognosis and molecular characteristics of clear-cell renal cell carcinoma: a multi-center integrated analysis of microbiome, metabo...
  Chen, W., Pan, X., Zhou, W., Xu, D., Chen, J., Dong, K., Chen, W., Cui, X., Rini, B.> ;Frontiers of Medicine. 2023 Dec 15
• Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 St...
  Plimack, E., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., Alekseev, B., Pouliot, F., Melichar, B., Soulières, D., Borchiellini, D., McDermott, R., Vynnyc...> ;European Urology. 2024 Feb 1
• LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
  Toni K Choueiri, Thomas Powles, Martin H Voss, Elizabeth R Plimack, Howard Gurney, Yue Song, Rodolfo F Perini, Karla Rodriguez-Lopez, Brian I Rini> ;Future Oncology. 2023 Dec 1
• Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 St...
  Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delph...> ;European Urology. 2023 Nov 1
• 1 citations
  Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma.
  Brian I Rini, Michael B Atkins, Toni K Choueiri, Rosemary E Teresi, Brad Rosbrook, Maghull Thakur, Thomas E Hutson> ;Future Oncology. 2023 Dec 1
• 6 citations
  Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
  Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delph...> ;European Urology. 2023 Nov 1
• A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma.
  Kathryn E Beckermann, Brian I Rini> ;Nature Reviews. Clinical Oncology. 2023 Sep 1
• Sequencing checkpoint inhibitor therapy in renal cell carcinoma.
  Kathryn E Beckermann, Brian I Rini> ;Lancet. 2023 Jul 15
• 2 citations
  Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
  Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, Errol J Philip, Daniela V Castro, JoAnn Hsu, Augusto Cesar de Andrade Mota, Andressa Cardoso de Azeredo, Jo...> ;The Oncologist. 2023 Jun 2
• 1 citations
  Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma.
  Brian I Rini, James Brugarolas, Michael B Atkins> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 2 citations
  Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination ther...
  Riveros, C., Ranganathan, S., Xu, J., Chang, C., Kaushik, D., Morgan, M., Miles, B., Muhammad, T., Anis, M., Aghazadeh, M., Zhang, J., Efstathiou, E., Klaassen, Z., Br...> ;Urologic Oncology. 2023 Mar 1
• 2 citations
  Adjuvant immunotherapy in renal cell carcinoma: a systematic review and meta-analysis.
  Carlos Riveros, Emily Huang, Sanjana Ranganathan, Zachary Klaassen, Brian Rini, Christopher J D Wallis, Raj Satkunasivam> ;BJU International. 2023 May 1
• 2 citations
  COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).
  Ana F Best, Melissa Bowman, Jessica Li, Grace E Mishkin, Andrea Denicoff, Marwa Shekfeh, Larry Rubinstein, Jeremy L Warner, Brian Rini, Larissa A Korde> ;Journal of the National Cancer Institute. 2023 May 8
• 5 citations
  Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma.
  Wen-Jin Chen, Ke-Qin Dong, Xiu-Wu Pan, Si-Shun Gan, Da Xu, Jia-Xin Chen, Wei-Jie Chen, Wen-Yan Li, Yu-Qi Wang, Wang Zhou, Brian Rini, Xin-Gang Cui> ;Cell Death & Disease. 2023 Jan 16
• 1 citations
  Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
  Luis Meza, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Sumanta K Pal, Brian Rini> ;The Oncologist. 2023 Mar 17
• 18 citations
  Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
  Brian I Rini, Sabina Signoretti, Toni K Choueiri, David F McDermott, Robert J Motzer, Saby George, Thomas Powles, Frede Donskov, Scott S Tykodi, Sumanta K Pal, Saurabh...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
• 8 citations
  Treatment of Refractory Metastatic Renal Cell Carcinoma.
  Joseph A Vento, Brian I Rini> ;Cancers. 2022 Oct 13
• 9 citations
  Emerging Targets in Clear Cell Renal Cell Carcinoma.
  Yu-Wei Chen, Brian I Rini, Kathryn E Beckermann> ;Cancers. 2022 Oct 4
• 79 citations
  Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomise...
  Sumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, Viraj A Master, Frede Donskov, Cristina Suarez, Laurence Albiges, Brian Rini, Yoshihiko Tomita, Ariel Galapo Kann, ...> ;Lancet. 2022 Oct 1
• 2 citations
  Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
  Zeynep B Zengin, Sumanta K Pal, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Brian Rini> ;Clinical Genitourinary Cancer. 2022 Dec 1
• 2 citations
  Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
  Patrick K Tamukong, Paige Kuhlmann, Sungyong You, Shengchen Su, Yanping Wang, Samantha Yoon, Jun Gong, Robert A Figlin, Jessica L Janes, Stephen J Freedland, Susan Hal...> ;Urologic Oncology. 2022 Nov 1
• Join now to see all

Journal Articles

• Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...  
  Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
• The Association Between Facility Case Volume and Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era  
  Timothy Gilligan, Jorge A Garcia, Brian I Rini, Urologic Oncology
• Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo‐Hormonal Therapy  
  Vadim Koshkin, Prateek Mendiratta, Brian I Rini, Pedro Barata, Christos Kyriakopoulos, Hamid Emamekhoo, Timothy Gilligan, The Prostate
• Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma  
  Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
• Targeted therapy for patients with renal-cell carcinoma.  
  Rini BI, Lancet Oncol. 2011 Nov;12(12):1085-7. Epub 2011 Oct 17. PMID: 22015058
• Commentary on "the impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor target...  
  Choueiri, T.K., Xie, W., Kollmannsberger, C., North, S., Knox, J.J., Lampard, J.G., McDermott, D.F., Rini, B.I., Heng, D.Y., Kidney Cancer Center, Dana Farber Cancer I..., J. Urol 2011; 185:60-6
• Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.  
  Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI, BJU Int. 2010 PMID: 20840548
• Emerging drugs for renal cell carcinoma.  
  Varella L, Rini BI, Expert Opin Emerg Drugs. 2010 Sep;15(3):343-53
• Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.  
  Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, Rini B, Ann Oncol. 2010 Aug;21(8):1618-22
• A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.  
  Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA, Invest New Drugs. 2010 Aug 14
• Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.  
  Mackenzie MJ, Rini BI, Elson P, Schwandt A, Wood L, Trinkhaus M, Bjarnason G, Knox J, Ann Oncol. 2010 Jul 1
• Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.  
  Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA, Cancer Res. 2010 May 1;70(9):3526-36
• Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.  
  Seliger B, Massa C, Rini B, Ko J, Finke J, Trends Mol Med. 2010 Apr;16(4):184-92
• Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based ch...  
  Dreicer R, Garcia J, Hussain M, Rini B, Vogelzang N, Srinivas S, Somer B, Zhao YD, Kania M, Raghavan D, Invest New Drugs. 2010 Apr 6
• Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated wi...  
  Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI, BJU Int. 2010 Mar 23
• Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction.  
  Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M, Rayman P, Rini B, Gill I, Tannenbaum CS, Finke JH, J Immunol. 183(8):5050-8, 2009
• Resistance to targeted therapy in renal-cell carcinoma.  
  Rini BI, Atkins MB, Lancet Oncol. 10(10):992-1000
• Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.  
  Rini BI, Cancer 115(10 suppl):2306-12
• Management of side-effects associated with sunitinib therapy for patients with renal cell carcinoma.  
  Rini BI, Dreicer R, OncoTargets and Therapy 2 51-61
• Renal cell carcinoma.  
  Rini BI, Campbell SC, Escudier B, Lancet 373:1119-32
• Sunitinib reverses type-1 immune suppression and Decreases T-regulatory cells in renal cell carcinoma patients.  
  Finke JH, Rini BI, Ireland J, Clinical Cancer Research 14(20):6674-82
• Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence.  
  Zhou M, Kort E, Hoekstra P, Rini BI, Lane B, American Journal of Surgical Pathology 33(1):72-78
• RCC – Progress in the management of small renal masses and advanced disease.  
  Campbell SC, Rini BI, Uzzo RG, AUA News, pages 4-7
• Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities.  
  Hansel DE, Rini BI, Expert Review, Anticancer Ther 8(6):895-905
• Axitinib for renal cell carcinoma.  
  Sonpavde G, Hutson TE, Rini BI, Expert Opinion Investig Drugs, 17(5):741-8
• Join now to see all

Books/Book Chapters

• Textbook of Uncommon Cancer. 
  Chapter: Uncommon Tumors of the Kidney 
  Khaled Ali, Ming Zhou, Steve Campbell, Ronald M. Bukowski and Brian I. RiniEditors: Derek Raghavan, Charles D. Blanke, David H. Johnson, Paul L. Moots, Gregory H. Reaman, Peter G. Rose.John Wiley & Sons, IncEdition 4,
• Renal Cell Carcinoma: Clinical Management. 
  Campbell SC, Rini BISpringer Science, Human Press, New York, NY
• Cancer Management: A Multi-disciplinary Approach. 
  Chapter: Urothelial and kidney cancers 
  Rini BI, Hurwitz MEdition 11,
• Prostate Cancer: A Clinical Guide. 
  Chapter: Biochemical recurrence of prostate cancer 
  Garcia JA, Rini BIEditors: Dahut WL, Gulley JL, Moul JW, Sandler HM.Lippincott, Williams, & Wilkins, Philadelphia, PA
• Cancer: Principles & Practice of Oncology. 
  Chapter: Kidney Cancer 
  Linehan M, Rini BI and Yang JCEditors: Drs. Vincent DeVita, Theodore Lawrence, and Steven Rosenberg.Edition 8,
• Manual of Cancer Medicine. 
  Rini BIEditors: Brown CK, Rini BI, Connell PP.BC Decker Inc, Hamilton
• Diseases of the Kidney and Urinary Tract. 
  Chapter: Primary Neoplams of the Kidney and Renal Pelvis 
  Rini BI, Ward J, Vogelzang NJLippincott Williams and WilkinsEdition 8,
• Prostate Cancer. 
  Chapter: Adjuvant Hormonal Therapy for Prostate Cancer 
  Page 464 - 473Rini BI, Vogelzang NJEditors: D’Amico A, Carroll P, Kantoff PW.Lippincott, Williams & Wilkins, Philadelphia, PA
• Everyone’s Guide to Cancer Therapy. 
  Chapter: Kidney Cancer 
  Page 582 - 588Rini BI, Torti FM and Small ESEditors: Dollinger M.Andrews McMeel, Kansas City, MO
• Join now to see all

Abstracts/Posters

• CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma.
  Rini BI, Halabi S, Rosenberg JE, Genitourinary Cancer Symposium, abstract 350
• Metastatic renal cell carcinoma (mRCC) with sarcomatoid component treated with VEGF-targeted therapy.
  Bukowski RM, Garcia JA, Rini BI, Genitourinary Cancer Symposium, abstract 348
• A prospective trial of Sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab.
  Rini BI, Hutson TE, Elson P, Garcia JA, Genitourinary Cancers Symposium, abstract 346
• Thyroid function test (TFT) abnormalities in patients with metastatic renal cell carcinoma (RCC) treated with sorafenib: 5048.
  IR Tamaskar, J Unnithan, JA Garcia, R Dreicer, L Wood, A Iochimescu, R Bukowski, Rini BI, Proc Am Soc Clin Oncol 25: 18S
• Safety of VEGF-targeted tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases: 5047.
  JS Unnithan, T Choueiri, J Garcia, R Dreicer, W Laura, R Bukowski, Rini BI, Proc Am Soc Clin Oncol 25: 18S
• Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy: 5046.
  A Golshayan, TK Choueiri, P Elson, JA Garcia, M Kasawneh, S Usman, I Tamaskar L Wood, Rini BI, Proc Am Soc Clin Oncol 25: 18S
• WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients receiving Sunitinib: 5043.
  S George, A Richmond, P Elson, T Jin, L Wood, JA Garcia, Rini BI, J Finke, RM Bukowski, Proc Am Soc Clin Oncol 25: 18S
• Treatment outcome for metastatic papillary and chromophobe renal cell Carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib: ...
  A Plantade, T Choueiri, B Escudier, Rini BI, S Negrier, A Ravaud, S Oudard, P Elson, R Bukowski, Proc Am Soc Clin Oncol 25: 18S
• Phase II trial of sunitinib in Bevacizumab-refractory Metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers: 5035.
  DJ George, MD Michaelson, JE Rosenberg, RM Bukowski, JA Sosman, WM Stadler, K Margolin, TE Hutson, Rini BI, Proc Am Soc Clin Oncol 25: 18S
• Axitinib (AG-013736: AG) in patients with metastatic renal cell cancer (RCC) refractory to sorafenib: 5032.
  Rini BI, GT Wilding, G Hudes, WM Stadler, S Kim, JC Tarazi, PW Bycott, KF Liau, JP Dutcher, Proc Am Soc Clin Oncol 25: 18S
• Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) targeted theapy in metastatic renal cell carc...
  TK Choueiri, SA Vaziri, Rini BI, P Elson, I Bhalla, E Jaeger, V Weinberg, FM Waldman M Zhou, RM Bukowski, R Ganapathi, Proc Am Soc Clin Oncol 25: 18S
• Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis: 5010.
  ME Gore, C Porta, S Oudard, G. Bjarnason, D. Castellano, C. Szczylik, PN Mainwaring, P Schoffski, Rini BI, RM Bukowski, Proc Am Soc Clin Oncol 25: 18S
• Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells.
  L Fong, B Kavanagh, Y Hou, S O’Brien, J Valiente, V Weinberg, Rini BI, EJ Small, Proc Am Soc Clin Oncol 25:18S
• Phase II of Sunitinib Malate (SU11248) in bevacizumab-refractory Metastatic Renal Cell Carcinoma.
  Rini BI, George DI, Michaelson MD, et al, Proc Am Soc Clin Oncol 17(9s)
• Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with bevacizumab.
  Shaheen PE, Tamaskar IR, Salas RN, Rini BI, Garcia J, Wood L, Dreicer R, Bukowski RM, 4605 Proc Am Soc Clin Oncol 24:18S
• Anti-proliferative effects of bevacizumab in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia.
  Al Hazzouri A, Vaziri SA, Lynch M, Schwartz B, Rini BI, Bukowski RM, Ganapathy R, Proc Am Soc Clin Oncol 24:18S
• Antitumor effects of bevacizumab and bevacizumab in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents.
  Tamaskar I, Shaheen P, Wood L, Hodnick S, Nemec C, Garcia J, Dreicer R, Rini BI, Bukowski RM, Proc Am Soc Clin Oncol 24:18S
• Phase II Study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (mRCC) 4539.
  Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia J, Mekhail T, Bukowski RM, Proc Am Soc Clin Oncol 24:18S
• Pharmacokinetics (PK) and efficacy of evacizum in patients with metastatic renal cell carcinoma (mRCC).
  Houk EB, Amantea M, Motzer RJ, Michaelson MD, Rini BI, George DJ, Redman BG, Hudes GR, Poland B, Bello CL, Proc Am Soc Clin Oncol 24:18S
• Efficacy and safety of bevacizumab malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).
  Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Margolin K, Hutson TE, Baum CM, Proc Am Soc Clin Oncol 24:18S
• T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during bevacizumab treatment: Correlations with clinical responses and T hel...
  Suppiah R, Finke J, Rini BI, Richmond A, Wood L, Elson P, Shaheen P, Garcia J, Dreicer R, Bukowski R, roc Am Soc Clin Oncol 24:18S
• A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer.
  Fong L, Kavanaugh B, Rini BI, Shaw V, Weinberg V, Small EJ, Proc Am Soc Clin Oncol 24:18S
• AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase II study of cytokine-refractory, metastatic renal cell cancer.
  Rini BI, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, et al, Proc Am Soc Clin Oncol 23:380
• A phase II trial of ketoconazole plus granulocyte/macrophage colony stimulating factor (GM-CSF) in androgen-independent prostate cancer patients.
  Lin AM, Ryan CJ, Rosenberg J, Rini BI, Nguyen T, Weinberg VI, Small EJ, Proc Am Soc Clin Oncol 23 :406
• Patient reported outcomes in a phase II trial of SU11248 for metastatic renal cell carcinoma.
  Beaumont J, Cella D, Li J, Motzer R, Rini BI, et al, Proc Am Soc Clin Oncol 23:770
• Join now to see all

Lectures

• Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion... 
  2019 ASCO Annual Meeting - 6/1/2019
• Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediat... 
  2019 ASCO Annual Meeting - 6/1/2019
• A Phase III Trial of Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Metastatic Renal Cell Carcinoma. 
  Genitourinary Cancer Symposium, Oral Presentation
• Kidney Cancer: Advances in the Management of SRM’s and Advanced Disease. 
  American Urological Association (AUA) Annual Meeting Course
• Making a Case for Initial Observation/Clinical Trial. 
  7th International Kidney Cancer Symposium
• Molecular Markers of Response & Resistance to VEGFR Inhibitors in RCC. 
  ASCO-NCI-EORTC Annual Meeting
• Pre-surgical Targeted Therapy in RCC. 
  ASCO Genitourinary Cancer Symposium
• Clinical Care Options: Master Class on Evolving Evidence & Emerging Treatments: Targeted Agents in Advanced RCC. 
• Management of Advanced Prostate Cancer; Renal Cancer; Management of Advanced Renal Cancer. 
  3rd Annual Perspectives in Genitourinary Oncology
• Individualized Therapy for Metastatic Renal Cell Carcinoma. 
  Dartmouth-Hitchcock Medical Center Grand Rounds
• Hypertension as a biomarker of efficacy in patients with mRCC treated with Sunitinib. 
  12th Annual Symposium on Anti-Angiogenic Agents
• Predictive Biomarkers for Targeted Therapy in Metastatic Renal Carcinoma. 
  UCLA Genitourinary GU Lecture
• Hypertension as a biomarker of clinical outcome with sunitinib in metastatic RCC. 
  Genitourinary Cancers Symposium
• Sunitinib Re-challenge in metastatic RCC. 
  Genitourinary Cancers Symposium
• Identification of Prognostic Genomic Markers in Patients with Localized Clear Cell Renal Cell Carcinoma. 
  Karmanos Cancer Institute Grand Rounds
• Switching to mTOR Inhibition vs. Maintaining VEGF Inhibition After VEGF Therapy Failure. 
  Ninth International Kidney Cancer Symposium
• Advances In the Treatment of Hormone-Refractory Prostate Cancer. 
  Multiple Locations, 2002
• AMG386 Alone or in Combination with Sorafenib: Results of a Randomized Phase II Trial. 
  Genitourinary Cancers Symposium
• Multidisciplinary Assessments in Advanced Renal Cell Carcinoma: Translating Evidence Into Practice. 
  ASCO GU Annual Meeting
• Non-myeloablative Allogeneic Transplantation for Metastatic Renal Carcinoma. 
  Multiple Locations, 2001, 2002
• Clinical Applications of Genomic Classification of RCC. 
  American Association for Cancer Research 102nd Annual Meeting
• High-dose Casodex in Prostate Cancer, Novel Treatments for Renal Carcinoma, Secondary Hormones for Prostate Cancer, Bladder Cancer – Advanced Disease Options & Early S... 
  UCSF Urology Seminar
• Bisphosphonates in Prostate Cancer. 
  Seton Medical Center Grand Rounds
• Inhibiting the VEGF Pathway in Renal Carcinoma. 
  Multiple Locations, 2003, 2004
• Kidney Cancer: New Advances in Treatment. 
  14th Annual Moll Pavilion Cancer Symposium
• Join now to see all

Other

• Kidney cancer: Does hypothyroidism predict clinical outcome? 
  Rini B, Nat Rev Urol. 2011 Jan;8(1):10-1. PMID: 21116300
• Editorial comment. 
  Rini BI, Shah SN, Urology. 2010 May;75(5):1114-5
• Editorial Comment. 
  Campbell SC, Rini BI, J Urol. 182(6):2599-600
• Lapatinib therapy for patients with advanced renal cell carcinoma. 
  Rini BI, Nat Clin Prac Oncol, 5(11):626-7
• Quantifying hypertension in patients with cancer treated with sorafenib. 
  Rini BI, Lancet Oncol. 9(2):86-7
• Commentary: Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma? 
  Rini BI, Nat Clin Prac Urol. 5(3):132-3
• Sorafenib in advanced renal cancer. 
  Rini BI, Drugs 67(3); 484-5
• Guest Commentary on: Stabilization of disease in patients with Metastatic Renal Cell Carcinoma using Sorafenib. 
  Rini BI, Nature Clinical Practice Oncology 3(11): 602-03
• Guest Commentary on Sorafenib in Advanced Renal Cancer. Adis Drug Profile. 
  Rini BI, American Journal of Cancer, 2006; 5(2)
• Management of Hormone-Sensitive Non-Metastatic Prostate Cancer. 
  Rini BI, Sandler HM, Wood DP, Report to the Nation on Prostate Cancer: Focus on Advanced Disease 2005 Professional Edition
• Validation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. 
  Rini BI, Nature Clinical Practice Oncology 2(5):2-3
• A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. 
  Rini BI, Vogelzang NJ, American Journal of Oncology Review. 3(8): 8-10
• Editorial comments on Management of renal carcinoma. 
  Rini BI, Vogelzang NJ, Oncology 14(1): 29-35
• Join now to see all